Sites
Tags
- 9
- A
- Abemaciclib
- Acalabrutinib
- Ace inhibitor
- Acetylcholinesterase inhibitor
- Acute lymphoblastic leukemia
- Adenosine deaminase
- Advances
- Afatinib
- Aflibercept
- Alanine transaminase
- Alectinib
- Alemtuzumab
- Alk-
- ALK inhibitor
- Alopecia
- Alpha-glucosidase inhibitor
- American Society of Health-System Pharmacists
- Amgen
- Amino Acid
- Aminolevulinic acid
- Amsacrine
- Anaplastic lymphoma kinase
- Anemia
- Annexin A2
- Anthracycline
- Anthraquinone
- Antimetabolite
- Apoptosis
- Aptamer
- ARIAD Pharmaceuticals
- Aromatase inhibitor
- Arsenic trioxide
- Ascó
- Asparaginase
- Asparagine
- Aspartate transaminase
- AstraZeneca
- Atezolizumab
- Atrasentan
- Avascular necrosis
- Avelumab
- Axicabtagene ciloleucel
- Axitinib
- Azacitidine
- Baricitinib
- Bayer
- Bcr-Abl tyrosine-kinase inhibitor
- Bendamustine
- Bevacizumab
- Binimetinib
- Bioaccumulation
- Bioavailability
- Biological half-life
- Bleomycin
- Blinatumomab
- Blood cell
- Blood plasma
- Blood proteins
- Boehringer Ingelheim
- Boosts
- Bortezomib
- Bosutinib
- BRAF
- Breakthroughs
- Breast
- Breast cancer
- Brentuximab vedotin
- Bristol Myer
- Bristol-Myers Squibb
- BRK
- Bruton's tyrosine kinase
- Budesonide
- Busulfan
- Cabazitaxel
- Cabozantinib
- Camptotheca
- Camptothecin
- Cancer
- Cancer immunotherapy
- Capecitabine
- Carbonic anhydrase inhibitor
- Carboplatin
- Carcinogenesis
- Cardio
- Cardiomyopathy
- Carfilzomib
- Carmustine
- CAS Registry Number
- CD117
- CD135
- CD20
- CD3
- CD52
- CDK inhibitor
- Cediranib
- Celecoxib
- Cell Cycle
- Cetuximab
- ChEMBL
- Chemical formula
- Chemotherapy
- ChemSpider
- Chlorambucil
- Chlormethine
- Chronic myelogenous leukemia
- Circulating tumor DNA
- Cisplatin
- Cladribine
- Clarithromycin
- Clinical trial
- Clinical Trials
- C-Met
- Cobimetinib
- Colorectal cancer
- Competitive inhibition
- Concentrated
- COX-2 inhibitor
- Crizotinib
- Crosstalk
- Cyclin-dependent kinase
- Cyclin-dependent kinase 4
- Cyclophosphamide
- CYP3A4
- Cytarabine
- Dacarbazine
- Dactinomycin
- DailyMed
- Daratumumab
- Dasatinib
- Daunorubicin
- Decitabine
- Demethylation
- Denileukin diftitox
- Department of Health
- Dipeptidyl peptidase-4 inhibitor
- DNA replication
- Docetaxel
- DOI
- Doxorubicin
- DR
- Drug
- DrugBank
- Drug metabolism
- Drug nomenclature
- Drugs.com
- Durvalumab
- Duvelisib
- Eflornithine
- Eisai
- Enasidenib
- Endothelin receptor antagonist
- Enfortumab vedotin
- Entinostat
- Enzyme
- Enzyme inhibitor
- Ephrin receptor
- Epidermal growth factor receptor
- Epirubicin
- Epithelial cell adhesion molecule
- Epothilone
- ErbB
- ERBB4
- Erdafitinib
- Erlotinib
- Etoposide
- European Chemicals Agency
- European Hematology Association
- European Medicines Agency
- Everolimus
- Exatecan
- Excretion
- Fedratinib
- Fibroblast growth factor receptor
- Fit
- Fludarabine
- Fluorouracil
- Food and Drug Administration
- Fostamatinib
- Frontiers
- Frontiers Media
- Fusion protein
- Gastrointestinal stromal tumor
- Gefitinib
- Gemcitabine
- Genentech
- Geron Corporation
- Girls
- Glasdegib
- GlaxoSmithKline
- Glioblastoma
- Grapefruit
- Halogenation
- Haloperidol
- Heart failure
- Hedgehog signaling pathway
- Hepatitis
- Hepatocellular carcinoma
- HER2/neu
- Histone deacetylase inhibitor
- Hoffmann-La Roche
- Hydrazine
- Hydrolase
- Hydroxycarbamide
- Hydroxylation
- Hygroscopy
- Hypercholesterolemia
- Hyperglycemia
- Hypertension
- Hypoglycemia
- Hypokalemia
- Hypomethylating agent
- Ibritumomab tiuxetan
- Ibrutinib
- Idarubicin
- Idelalisib
- Ifosfamide
- Ileus
- Imatinib
- ImmunoGen
- Immunotherapy
- Incyte
- Inflammation
- Integrase inhibitor
- Intercalation
- Interleukin 2
- International Chemical Identifier
- Interstitial lung disease
- Ipilimumab
- Irinotecan
- Isatuximab
- Ixabepilone
- Janssen Biotech
- Janus kinase
- Janus kinase inhibitor
- Jmol
- Karshi-Khanabad Air Base
- KEGG
- Ketoconazole
- Kinase
- Kinase insert domain receptor
- Kraš
- Lapatinib
- Laura Trial
- Lenvatinib
- Leukemia
- Liver failure
- Lomustine
- Long QT syndrome
- Lonidamine
- Lorlatinib
- Lucanthone
- Lung cancer
- Lung cancer treatment
- Lyase
- Lymphatic system
- Lymphoma
- Macular degeneration
- Macular edema
- Media of the United Kingdom
- Medical Subject Headings
- Medication
- MedlinePlus
- Medullary thyroid cancer
- MEK inhibitor
- Melanoma
- Melphalan
- Mercaptopurine
- Methotrexate
- Microtubule
- Midazolam
- Midostaurin
- Mitomycins
- Mitotane
- Mitotic inhibitor
- Mitoxantrone
- Molar mass
- Momelotinib
- Monoamine oxidase inhibitor
- Monoclonal antibody therapy
- Most
- MTOR inhibitors
- Mubritinib
- Myelofibrosis
- Myeloid
- Myers Squibb
- National Health Service
- National Institute for Health and Care Excellence
- Nausea
- Navitoclax
- Nektar Therapeutics
- Neoplasm
- Nephrotic syndrome
- Neratinib
- Neuraminidase inhibitor
- Neuroblastoma
- Neuroinflammation
- Neutropenia
- New
- New Frontier
- New Frontiers
- Nilotinib
- Nintedanib
- Niraparib
- Nitrogen
- Nivolumab
- Non-competitive inhibition
- Non-small-cell lung carcinoma
- Novartis
- Obesity
- Ofatumumab
- Olaparib
- Oncology
- OnyX
- Oral administration
- Osimertinib
- OSI Pharmaceuticals
- Oxaliplatin
- Oxidoreductase
- Paclitaxel
- Pacritinib
- Palbociclib
- Pancreatic cancer
- Pancreatitis
- Panobinostat
- PARP inhibitor
- PDGFRB
- Pembrolizumab
- Pemetrexed
- Pertuzumab
- Pfizer
- Pharmaceutics
- Pharmacokinetics
- Pharmacology
- Phases of clinical research
- Pheochromocytoma
- Philadelphia chromosome
- Phosphate
- Phosphodiesterase inhibitor
- Phosphoinositide 3-kinase inhibitor
- Phosphorylation
- Photodynamic therapy
- Photosensitivity
- Photosensitizer
- Placebo
- Plasma protein binding
- Platform
- Platinum-based antineoplastic
- PMC
- Podophyllum
- Polymerase chain reaction inhibitors
- Porphyrin
- Prescription drug
- Procarbazine
- Progression-free survival
- Prohibitin
- Protease inhibitor
- Proteasome inhibitor
- Protein
- Protein kinase
- Protein kinase inhibitor
- PubChem
- PubMed
- Purine analogue
- QT interval
- Quizartinib
- Raltitrexed
- Ramucirumab
- Ranibizumab
- Receptor antagonist
- Receptor tyrosine kinase
- Regeneron
- Regorafenib
- Regulation of therapeutic goods
- Renal cell carcinoma
- Result
- Retinoid
- Reverse-transcriptase inhibitor
- Rhabdomyolysis
- Rheumatoid arthritis
- Ribociclib
- Rifampicin
- Ritonavir
- Rituximab
- ROS1
- Route of administration
- Rucaparib
- Ruxolitinib
- Sacituzumab govitecan
- Selumetinib
- Semustine
- Serine
- Sex steroid
- Shingles
- SIRT
- Small molecule
- Society of Nuclear Medicine and Molecular Imaging
- Soft-tissue sarcoma
- Sorafenib
- S phase
- Squamous cell carcinoma
- SRC
- Standard for the Uniform Scheduling of Medicines and Poisons
- Star Wars sequel trilogy
- Statin
- Stevens–Johnson syndrome
- St John's wort
- Streptomyces
- Streptozotocin
- Succinic acid
- SUGEN
- Suggest
- Sunitinib
- Susan G. Komen for the Cure
- Syk
- Takeda Pharmaceutical Company
- Talimogene laherparepvec
- Targeted therapy
- Taxane
- Temozolomide
- Testolactone
- Teva Pharmaceutical Industries
- The guardian
- Therapy
- Thiopurine
- ThioTEPA
- Three
- Threonine
- Thyroid cancer
- Tigilanol tiglate
- Tioguanine
- Tisagenlecleucel
- Tivozanib
- Tofacitinib
- Topoisomerase inhibitor
- Topotecan
- Torsades de pointes
- Tositumomab
- Toxic epidermal necrolysis
- Trabectedin
- Trametinib
- Transferase
- Transient ischemic attack
- Transport protein
- Trastuzumab
- Trastuzumab emtansine
- Treatment of cancer
- Tremelimumab
- Treosulfan
- Tretinoin
- Tropomyosin receptor kinase A
- Tropomyosin receptor kinase B
- Tuberculosis
- Tumor
- Tumor suppressor gene
- Type II topoisomerase
- Type I topoisomerase
- Tyrosine
- Tyrosine kinase
- Tyrosine-kinase inhibitor
- U.K.
- Uncompetitive inhibitor
- Unique Ingredient Identifier
- Urinary tract infection
- Valrubicin
- Vascular endothelial growth factor
- Vascular endothelial growth factor A
- V. Craig Jordan
- VEGFR1
- VEGF receptor
- Vemurafenib
- Venetoclax
- Verteporfin
- Vinblastine
- Vincristine
- Vinflunine
- Vinorelbine
- Vismodegib
- Vorinostat
- WebMD
- What
- WHO Model List of Essential Medicines
- Youthful
- Β-Lactamase inhibitor